Search

Your search keyword '"McCabe, Francis L."' showing total 23 results
Start Over Author "McCabe, Francis L."
23 results on '"McCabe, Francis L."'

2. Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function

Author

Grugan, Katharine D., primary, McCabe, Francis L., additional, Kinder, Michelle, additional, Greenplate, Allison R., additional, Harman, Benjamin C., additional, Ekert, Jason E., additional, van Rooijen, Nico, additional, Anderson, G. Mark, additional, Nemeth, Jeffrey A., additional, Strohl, William R., additional, Jordan, Robert E., additional, and Brezski, Randall J., additional

Published
2012
Full Text
View/download PDF

3. Abstract 2334: A novel αV integrin antibody, intetumumab (CNTO 95), enhances anti-tumor activity against human non-small cell lung cancer through disruption of the FAK/ERK/AKT pathway and regulation of p27KIP1

Author

Heidrich, Bradley J., primary, Chen, Qiming, additional, Macedo, Luciana, additional, Ferrante, Catherine A., additional, Wiley, Diana, additional, McCabe, Francis L., additional, Doshi, Parul, additional, and Marshall, Deborah J., additional

Published
2010
Full Text
View/download PDF

5. CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells

Author

Chen, Qiming, primary, Manning, Carol D., additional, Millar, Hillary, additional, McCabe, Francis L., additional, Ferrante, Catherine, additional, Sharp, Celia, additional, Shahied-Arruda, Lillian, additional, Doshi, Parul, additional, Nakada, Marian T., additional, and Anderson, G. Mark, additional

Published
2007
Full Text
View/download PDF

9. High-Dose Recombinant Interleukin-18 Induces an Effective Th1 Immune Response to Murine MOPC-315 Plasmacytoma

Author

Jonak, Zdenka L., primary, Trulli, Stephen, additional, Maier, Curtis, additional, McCabe, Francis L., additional, Kirkpatrick, Robert, additional, Johanson, Kyung, additional, Ho, Yen Sen, additional, Elefante, Louis, additional, Chen, Yi-Jiun, additional, Herzyk, Danuta, additional, Lotze, Michael T., additional, and Johnson, Randall K., additional

Published
2002
Full Text
View/download PDF

13. Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

Author

Kingsbury, William D., primary, Boehm, Jeffrey C., additional, Jakas, Dalia R., additional, Holden, Kenneth G., additional, Hecht, Sidney M., additional, Gallagher, Gregory, additional, Caranfa, Mary Jo, additional, McCabe, Francis L., additional, Faucette, Leo F., additional, Johnson, Randall K., additional, and Hertzberg, Robert P., additional

Published
1991
Full Text
View/download PDF

14. Circulating Human lnterleukin-8 as an Indicator of Cancer Progression in a Nude Rat Orthotopic Human Non-mall Cell Lung Carcinoma Model.

Author

Millar, Hillary J., Nemeth, Jeffrey A., McCabe, Francis L., Pikounis, Bill, and Wickstrom, Eric

Abstract

The article reports on results of a study of circulating human interleukin-8 (IL-8) as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. A description of the experimental set-up and measurement method is provided. The study concluded that circulating human IL-8 is a relevant tumor protein marker due to its positive correlation with multiple physiologic variables associated with lung cancer progression.

Published
2008
Full Text
View/download PDF

16. Nonproductive Rearrangement of DNA Topoisomerase I and II Genes: Correlation With Resistance to Topoisomerase Inhibitors.

Author

Tan, K. B., Mattern, Michael R., Eng, Wai-Kwong, McCabe, Francis L., and Johnson, Randall K.

Abstract

Topoisomerase inhibitors comprise an important group of agents that is used in cancer treatment. Because the development of resistance to cancer chemotherapeutic agents represents a major limitation of cancer chemotherapy, we investigated the mechanism of resistance by murine P388 leukemia to camptothecin (topoisomerase I inhibitor) or amsacrine (topoisomerase II inhibitor). The resistant cells contained reduced levels of topoisomerase activity and messenger RNA. The topoisomerase gene of these cells was rearranged (only in one allele) and hypermethylated. These topoisomerase gene alterations probably resulted in reduced transcription and, thus, enzyme production, which was correlated with resistance to the topoisomerase inhibitor. [J Natl Cancer Inst 81:1732–1735, 1989] [ABSTRACT FROM PUBLISHER]

Published
1989

17. Keynotes.

Author

Jonak, Zdenka L., Trulli, Stephen, McCabe, Francis L., Taylor, Alexander, Elefante, Louis, Yi-Jiun Chen, Fishman-Lobell, Jacqueline, Johanson, Kyung, Mattern, Michael R., Lotze, Michael T., Johnson, Randall, Capra, J. Donald, Larrick, James W., Yu, Lloyd, Naftzger, Clarissa, Jaiswal, Sudhir, and Wycoff, Keith

Subjects
IMMUNOGLOBULINS, TUMOR treatment, LYMPHOCYTES
Abstract

Summarizes different research papers on antibodies and other related topics. Analysis of immunological mechanisms in the development of anti-tumor drug; Discussion on lymphocyte subsets; Study of human antibodies in clinical trials.

Published
2001
Full Text
View/download PDF

23. Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models.

Author

Chen Q, Millar HJ, McCabe FL, Manning CD, Steeves R, Lai K, Kellogg B, Lutz RJ, Trikha M, Nakada MT, and Anderson GM

Subjects
Animals, Antibodies, Monoclonal immunology, Antibodies, Monoclonal, Humanized, Antibody Specificity, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Cell Line, Tumor, Drug Delivery Systems, Female, Flow Cytometry, Humans, Immunoconjugates chemistry, Immunotherapy, Mice, Rats, Xenograft Model Antitumor Assays, Antibodies, Monoclonal administration & dosage, Antineoplastic Agents administration & dosage, Immunoconjugates administration & dosage, Integrin alpha5 immunology, Neoplasms, Experimental drug therapy
Abstract

Purpose: Targeted delivery of cytotoxic agents to solid tumors through cell surface antigens can potentially reduce systemic toxicity and increase the efficacy of the targeted compounds. The purpose of this study was to show the feasibility of treating solid tumors by targeting alpha(v) integrins with antibody-maytansinoid conjugates and to test the relative in vivo activities of several linker-maytansinoid chemistries., Experimental Design: CNTO 364, CNTO 365, and CNTO 366 are targeted cytotoxic agents created by conjugating the CNTO 95 anti-alpha(v) integrin antibody with three distinct maytansinoid-linker structures. These structures were designed to have varying degrees of chemical substitution surrounding the disulfide bond linking the cytotoxic agent to the antibody. A model conjugate was shown to be specifically cytotoxic in vitro and highly active against established human tumor xenografts in immunocompromised rats. The in vivo antitumor activities of CNTO 364, CNTO 365, and CNTO 366 were compared in rat xenograft models., Results: CNTO 365, with a linker chemistry of expected intermediate stability, was shown to be substantially more active than the other two conjugates with lesser or greater substitution around the disulfide linkage., Conclusion: CNTO 95-maytansinoid immunoconjugates are potent antitumor agents against alpha(v) integrin-expressing human carcinomas. These studies show for the first time the feasibility of targeting alpha(v) integrins on solid tumors with tumor-activated prodrugs. The DM4 linker-maytansinoid configuration of CNTO 365 was substantially more active in the models tested here when compared with alternative configurations with greater or lesser chemical substitution surrounding the linker.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results